IDYA Unusual Options Activity — 2026-04-06

🧬 IDYA $10.6M Butterfly Loaded Ahead of Phase 3 Data Drop - Smart Money Positions for Darovasertib Catalyst!

📅 April 6, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

In the span of 52 seconds, someone built a $10.6 million long call butterfly on IDEAYA Biosciences - buying 12,000 $40 calls and selling 6,000 $35 calls and 6,000 $45 calls, all expiring May 15, 2026. This is no accident: IDYA's OptimUM-02 Phase 2/3 pivotal trial for darovasertib completed its database lock in the first half of April, with topline PFS results expected imminently. At $32.44 spot, the $40 center strike is 23% out of the money. This trade is not a bet on a quiet stock gently drifting up. This is a precision volatility play positioning for a binary binary-type data catalyst - and the butterfly structure itself tells you the trader expects a significant move, but wants to profit in a defined range around $40 rather than pay for unlimited upside.

The bottom line: Institutional money just paid up to own the $40 zone through a data event that could confirm a first-ever approved therapy in metastatic uveal melanoma - one of the rarest and most lethal ocular cancers with almost no approved treatment options today.

---

📊 Company Overview

IDEAYA Biosciences (IDYA) is a clinical-stage precision medicine oncology company focused on synthetic lethality and targeted oncology:

• 🧬 What they do: Discovers and develops targeted therapeutics for oncology patients with specific genetic profiles, leveraging synthetic lethality biology across multiple tumor types including uveal melanoma, SCLC, breast cancer, lung, pancreatic, and urothelial cancers
• 💰 Market Cap: ~$2.5B
• 🏢 Sector: Biotechnology / Precision Oncology
• 📈 Exchange: NASDAQ
• 📊 Current Price: ~$32.43
• 💵 Cash Runway: $1.05 billion as of Dec 31, 2025, funding operations into 2030
• 🎯 Key Story: Lead asset darovasertib (IDE196) is a PKC inhibitor targeting GNAQ/GNA11-mutated tumors, being evaluated in three Phase 3 registrational trials in uveal melanoma. OptimUM-02 Phase 2/3 topline PFS data is due imminently - the most binary, high-impact catalyst in the company's history

---

💰 The Option Flow Breakdown

📊 The Tape

🤓 What This Actually Means

Let me decode this 52-second sequence:

The construction (in order of execution):

1. 14:12:37 → SELL 6,000 x $35 calls at $6.40 → collect $3.84M
2. 14:12:39 → BUY 6,000 x $40 calls at $4.25 → pay $2.55M
3. 14:12:41 → SELL 6,000 x $45 calls at $2.60 → collect $1.56M
4. 14:13:29 → BUY 6,000 x $40 calls at $4.25 → pay $2.55M (doubling the long wing)

This creates a classic Long Call Butterfly:

• 🦋 Buy 12,000 x $40 calls (body - long 2x center)
• 🦋 Sell 6,000 x $35 calls (lower wing - short)
• 🦋 Sell 6,000 x $45 calls (upper wing - short)

Net premium paid:

• Total paid: (12,000 × $4.25 × 100) = $5.10M
• Total collected: (6,000 × $6.40 × 100) + (6,000 × $2.60 × 100) = $3.84M + $1.56M = $5.40M
• Net credit received: ~$300K (or nearly a very low-cost, near-zero net debit position given bid-ask spread friction; this may be slightly negative in practice)

In practical terms: the $35 write offsets the premium of the lower $40 calls, and the $45 write offsets the premium of the upper $40 calls. The trader owns the $40 center cheaply - financed largely by the wings.

Key metrics:

• 🦋 Structure: Long Call Butterfly centered at $40
• 📊 Vol/OI on $40 calls: 75.9x - existing OI of only 158 contracts; 12,000 contracts traded today = 100% new position
• 📊 Vol/OI on $35 calls: 86.5x - OI 74; massively exceeds prior open interest
• 📊 Vol/OI on $45 calls: 80x - OI 75; same story
• 🤝 All MID fills: Every single leg executed at the midpoint - textbook institutional block negotiation
• 🎯 Z-scores: All four legs classified as EXTREMELY UNUSUAL (503x, 179x, 251x, 294x standard deviations above typical)
• ⏰ 39 days to expiration (May 15): Tight window designed to bracket the OptimUM-02 data readout + Q1 2026 earnings (expected ~May 5)

Why a butterfly and not outright calls?

This structure tells you the trader believes IDYA will have a significant move - but wants to profit in a defined price zone ($35-$45) rather than pay for unlimited upside. At $32.44 spot:

• If the data is positive and the stock rallies +23% to $40, this position reaches its maximum profit zone
• If the data is spectacularly good and the stock rockets past $45, profits start declining
• If the data is negative and the stock falls hard below $35, the loss is capped at the net premium paid
• The $35 short call is currently slightly in the money ($32.44 vs $35 strike) - the trader sold it to finance the position, accepting that they cap any profit below $35

This is a nuanced, sophisticated trade. It is not a panic buy of calls. It is a precision bet on the stock landing in the $40-$45 zone post-catalyst.

---

📈 Technical Setup / Chart Check-Up

YTD Performance

IDYA has experienced significant volatility consistent with a binary clinical-stage biotech name. Key technical observations:

• 📉 Sharp recent sell-off: The stock is down substantially from its 52-week highs, trading at ~$32.44 today versus analyst consensus targets of $50-$52 - a ~37% discount to the Street's view
• 🌊 Macro headwinds: Broad biotech weakness from tariff uncertainty and risk-off sentiment in April 2026 has created an indiscriminate sell-off, pressuring IDYA along with the sector
• 📊 Volume profile: Today's butterfly involved 12,000 long $40 contracts vs prior OI of 158 - the options market for IDYA was essentially empty before this trade. Someone chose to initiate a massive position from scratch
• 🎯 $32-$33 current range: The stock is holding up relatively well for a pre-data binary event, suggesting some baseline support from cash value ($1.05B in cash = ~$13/share) and pipeline optionality
• 📈 Distance to butterfly peak: Stock needs to rally +23% from $32.44 to reach $40 center of maximum profit - achievable in a positive data scenario for a small-cap biotech

Gamma-Based Support & Resistance Analysis

Current Price: $32.49

The gamma exposure map for IDYA is relatively sparse given the stock's small options market, but reveals meaningful structure:

🔵 Support Levels (Put Gamma Below Price):

• $30.00 - Strongest put gamma support with 0.285B net GEX (-0.213B net)
  • Distance: 7.7% below current price
  • This represents a meaningful floor where dealer hedging flows become supportive
  • Importantly, this aligns with psychological round number support and approximately $30 = ~"cash-like" biotech floor territory

🟠 Resistance Levels (Call Gamma Above Price):

• $35.00 - Dominant call gamma resistance with 0.976B total GEX (+0.758B net)
  • Distance: 7.7% above current price
  • Note: The $35 is the short call strike in this butterfly - the trader sold this level intentionally, implicitly agreeing it acts as resistance in the near term
  • The substantial call gamma here creates a natural "ceiling" that dealers will resist - consistent with the trader selling against it

Net GEX Bias: Bullish (1.37B total call GEX vs 0.73B put GEX) - dealer positioning overall leans bullish, but the $35 resistance is real and heavy. A catalyst strong enough to push through $35 gamma resistance is what this butterfly needs to generate its maximum payoff near $40.

Key insight: The butterfly's lower short strike at $35 perfectly aligns with the largest gamma resistance cluster. The trader is essentially selling what the market already sees as a cap - while buying the $40 zone where gamma is currently absent, creating a levered payoff if the stock breaks above that resistance on the data catalyst.

Implied Move Analysis

Options market pricing for upcoming expirations:

• 📅 Monthly OPEX (April 17 - 11 days): ±$5.25 (±16.1%) → Range: $27.35 - $37.85

Translation: The options market is pricing a 16.1% swing for IDYA through the April 17 OPEX. This elevated implied move reflects the imminent OptimUM-02 data readout. A positive clinical data surprise could easily produce a 25-40%+ upside move (consistent with biotech Phase 3 readout dynamics), placing the stock squarely in the butterfly's profit zone around $40. The upper range of the April implied move ($37.85) is still below the $40 center strike - this May 15 butterfly is betting the catalyst produces a move beyond what the near-term market is currently pricing.

---

🎪 Catalysts

🔥 The #1 Catalyst: OptimUM-02 PFS Topline Data - IMMINENT 🚨

This is the most binary event in IDEAYA's history and the clear driver of this options trade.

The Phase 2/3 OptimUM-02 registrational trial evaluates darovasertib + crizotinib in first-line HLA*A2-negative metastatic uveal melanoma (mUM):

• 👥 435 patients enrolled across 60+ global sites
• 📊 130 PFS events confirmed by blinded independent central review (BICR) - the predefined endpoint for the primary analysis
• 📅 Database lock: First half of April 2026 (per March 22 guidance) - meaning results are likely days to weeks away
• ⚡ If positive: Enables a potential accelerated approval filing with the FDA in the United States - first ever approved therapy for mUM
• 🎯 Benchmark to beat: Single-agent historical control median PFS of ~3 months in mUM; prior Phase 1/2 data showed darovasertib + crizotinib achieving median PFS of ~7 months with ORR >30% vs ~10% for SOC

Why this matters so much: Metastatic uveal melanoma is an extremely rare, lethal cancer with no currently approved systemic therapies. Median survival from metastasis is typically 6-12 months. A positive OptimUM-02 readout would create a first-in-class drug in an orphan indication with high pricing power, rapid regulatory pathway, and essentially no competitive alternatives. This is a potential $500M+ peak revenue asset in an ultra-orphan market - and 14 analysts have rated IDYA a Strong Buy in anticipation.

The delay story: Originally guided for end-of-March 2026, IDEAYA disclosed on March 22 that database lock was pushed to first half of April due to operational logistics of data verification across 60+ international sites. RBC Capital reiterated its buy rating on the delay, viewing it as procedural and not a sign of negative data. The delay may have actually contributed to the stock's recent weakness - and created the entry point this butterfly trader is exploiting.

🔥 Upcoming Catalysts

Q1 2026 Earnings - Expected ~May 5, 2026 📊

Back-to-back catalyst with the May 15 expiration:

• Cash burn rate and updated runway guidance
• Any preliminary commercial readiness updates for darovasertib (if accelerated approval path is initiated)
• IDE849 Phase 1 data update in small cell lung cancer (SCLC) and neuroendocrine cancers
• IDE034 Phase 1 dose escalation first-patient-in update
• IDE161 (PARG inhibitor) combination study initiation update

Three Phase 3 Registrational Trials by H1 2026 🚀

IDEAYA is building toward having darovasertib in three simultaneous Phase 3 trials:

1. OptimUM-02 (mUM, 1L HLA*A2-negative) - data imminent
2. Neoadjuvant setting (primary uveal melanoma, pre-surgery)
3. Adjuvant setting (post-surgical maintenance)

The ESMO 2025 proffered paper presentation for darovasertib in neoadjuvant primary UM showed positive Phase 2 data, adding pipeline depth beyond the immediate mUM opportunity.

IDE849 (PARP-independent mechanism, SCLC/NEC) - Data Update 2026 📈

IDE849 is IDEAYA's clinical-stage asset targeting a novel synthetic lethality approach in small cell lung cancer and neuroendocrine cancers. A preliminary Phase 1 data update and potential monotherapy registrational study initiation in 2L+ SCLC/NEC is expected by end of 2026. SCLC is a far larger indication than mUM, making IDE849 the potential long-duration growth driver.

IDE034, IDE161, IDE397 (Multiple Early-Stage Programs) 🔬

IDEAYA filed four INDs in 2025, now running nine clinical programs. IDE161 (PARG inhibitor) and IDE397 (MAT2A) are both in Phase 1/2 combination studies. This pipeline depth is a key reason analysts maintain $50+ price targets even with the stock at $32.

Bank of America Healthcare Conference - May 12, 2026 🎤 Stifel Targeted Oncology Virtual Forum - May 19, 2026 🎤

Both events post-expiration but likely occasions for management to discuss OptimUM-02 results and next regulatory steps - important for the stock's longer-term trajectory.

✅ Recent Catalysts (Already Happened)

Q4 2025 / Full Year 2025 Earnings - February 17, 2026 💰

IDEAYA reported:

• Net loss of $83.3M in Q4 2025 (36% improvement YoY)
• Cash position: $1.05B as of Dec 31, 2025
• Runway extended to 2030 - no financing risk
• 2026 objectives outlined: OptimUM-02 readout, three Phase 3 registrational programs, IDE849 update

OptimUM-02 Full Enrollment Completed - December 11, 2025 📋

435 patients enrolled, 130 BICR-confirmed PFS events triggered the primary analysis. Full enrollment enables the company to also pursue full approval (beyond accelerated approval) once OS data matures.

ESMO 2025 Darovasertib Neoadjuvant Data - 2025 📊

Positive Phase 2 proffered paper oral presentation on darovasertib in the neoadjuvant setting of primary uveal melanoma - broadening the addressable clinical opportunity beyond the metastatic setting.

First-Patient-In for IDE849 and IDE161 Studies - March 30, 2026 🔬

Most recent news: Two additional programs entered clinical dosing just one week ago, continuing IDEAYA's pipeline momentum regardless of the OptimUM-02 outcome.

---

🎲 Price Targets & Probabilities

Using gamma levels, implied move data, analyst targets, and the catalyst calendar, here are the scenarios through the May 15, 2026 expiration:

📈 Bull Case - Positive OptimUM-02 Data (40% probability)

Target: $40-$55+

How we get there:

• ✅ OptimUM-02 shows statistically significant PFS improvement (median PFS 7+ months vs ~3 months control)
• 🚀 Accelerated approval filing initiated in the US
• 📊 14 analysts at "Strong Buy" with ~$50 average target upgrade this scenario significantly
• 💊 First-ever approved therapy for mUM creates pricing power narrative
• 📈 Stock rallies 25-70%+ on positive readout (consistent with biotech binary event dynamics)
• 🎯 Butterfly maximum profit zone: $35-$45, centered on $40

Butterfly P&L at various price points:

Max profit scenario: Stock lands in the $38-$42 zone on the data readout. Positive enough to rally hard, but not so explosive it blows through $45 and out of the profit zone. At a $40 settlement, each butterfly spread earns $5 minus the net debit (~$0-$0.40 in net premium depending on fills). On 6,000 butterflies, that's roughly $2.7M-$3M profit on the net spread.

🎯 Base Case - Modest Positive / Mixed Signal (35% probability)

Target: $33-$40 range

Most likely scenario:

• ✅ Data is directionally positive but statistical bar is met conservatively
• 📊 Stock reacts with a 10-25% bounce
• ⏰ Regulatory filing timeline and OS maturation discussion dominate conference call narrative
• 📈 Butterfly captures partial profit if stock gets to $37-$40

Trading implications: The butterfly still profits in this scenario if the stock clears $35 decisively. At $38, the position is earning meaningful return. The May 15 expiration gives 39 days to monetize the position even if the initial pop takes the stock to $37-$38.

📉 Bear Case - Negative Data (25% probability)

Target: $15-$28

What could go wrong:

• 😰 OptimUM-02 misses the PFS endpoint (trial fails primary endpoint)
• 📉 Stock collapses 30-60%+ (typical failed Phase 3 biotech reaction)
• 💸 Butterfly trader loses the net premium paid (likely a small net credit or minimal net debit)
• ⚠️ $30 gamma support gets obliterated; stock could trade toward $20 or lower
• 🔄 Focus shifts entirely to IDE849 and longer-dated pipeline - the stock rerate takes years

Critical insight on the butterfly's bear case: This is where the structure is elegant. If the data is negative and IDYA falls to $20-$25, the butterfly expires worthless on all legs - the short $35 and $45 calls also expire worthless, and the $40 calls expire worthless. The maximum loss is the net debit paid on the spread, which in this case appears to be near-zero or a small credit. The butterfly trader's downside on negative data is essentially their transaction costs and bid-ask spread losses - a remarkably efficient structure for a binary event.

This is the key insight: the butterfly was constructed to have essentially free or very cheap exposure to the positive data scenario, while capping the loss if the trial fails.

---

💡 Trading Ideas

🛡️ Conservative: "Follow the Catalyst, Control the Risk" - May $35/$40 Bull Call Spread

Play: Buy the IDYA May 15 $35 calls, sell the May 15 $40 calls

Structure: $35/$40 debit call spread, same expiration as the institutional butterfly

Why this works:

• 📊 Captures the directional thesis (positive data → stock to $35-$40+) at a defined cost
• 🛡️ Max loss: net debit paid (~$1.50-$2.50 per spread, depending on fills)
• 💰 Max profit: $5 per spread minus debit = ~$2.50-$3.50 gain (1.5-2x the investment)
• ⏰ Same 39-day window captures the data readout and Q1 earnings double-catalyst
• 🎯 Breakeven at approximately $36.50-$37.50 at expiration
• 📈 The $35 lower strike is at current gamma resistance - a break above that level on the data would be a meaningful signal

Position sizing: Risk no more than 3% of portfolio. 20 spreads at ~$2.00 each = $4,000 at risk for $6,000-$7,000 max profit.

Risk level: Moderate (defined risk, binary catalyst) | Skill level: Intermediate

⚖️ Balanced: "Mirror the Whale" - Call Butterfly $35/$40/$45

Play: Build a smaller version of the institutional butterfly: Buy 2x $40 calls, sell 1x $35 call, sell 1x $45 call (all May 15)

Why this works:

• 🦋 Mirrors the exact structure that $10M+ of institutional money just built at MID
• 💸 Net cost is minimal-to-zero - the wings largely finance the center
• 📊 Maximum profit if stock settles near $40 at expiration
• ⏰ Designed specifically around the OptimUM-02 data readout + earnings double catalyst
• 🎯 Best scenario: stock rallies 23% on positive data to the $40 zone exactly
• 📈 Sophisticated vol play: if IV crush post-data is dramatic but the stock doesn't go much above $45, all legs decay together

Position sizing: 5 butterflies (buy 10x $40, sell 5x $35, sell 5x $45). If net debit is $0.40, total risk = $200. If net credit, you actually collect premium.

Risk level: Low-Moderate (near-zero cost, binary directional catalyst) | Skill level: Advanced

🚀 Aggressive: "All-In on Approval" - May $40 Calls Outright

Play: Buy IDYA May 15 $40 calls outright at ~$4.25

Why this works (and why it is extremely risky):

• 💥 Uncapped upside if IDYA rockets 50-70%+ on positive data
• 📊 Same strike as the institutional trade - they paid $4.25; you would too
• ⏰ 39 days captures both the data readout and Q1 2026 earnings
• 🚀 A failed Phase 3 in mUM is not the end of IDYA - IDE849 and the pipeline remain, so the stock may not go to zero even on a miss

Why it will likely blow up:

• 💸 If data is negative, $4.25 premium goes to $0 rapidly
• ⏰ 39 days - time decay accelerates dramatically once the data event passes
• 📉 Stock needs to get above $44.25 at expiration just to break even
• 🎢 IV crush after the data announcement (regardless of direction) could cut the option's value by 40-50% even if the stock moves favorably
• ⚠️ The institutional buyer complemented these calls with a butterfly structure - suggesting even they wanted to cap cost

Position sizing: Risk ONLY what you can afford to lose completely. 10 contracts = $4,250 at risk. Do not exceed 1-2% of portfolio.

Risk level: VERY HIGH (can lose 100% of premium) | Skill level: Advanced

---

⚠️ Risk Factors

Don't get caught by these potential landmines:

• 🧪 Binary trial risk is existential for near-dated options: A failed OptimUM-02 primary PFS endpoint would likely send IDYA down 35-60%+ in a single session. With 39 days to May 15 expiration and the $40 strike 23% OTM, outright $40 calls expire worthless in this scenario. The butterfly structure addresses this by making the downside cost essentially zero - retail traders in naked calls cannot say the same.

• ⏰ "When exactly?" uncertainty is real: The database lock is "first half of April." That means anywhere from April 1-15. Topline analysis then follows. The results could drop April 7 or April 20 - the uncertainty creates a complex gamma environment where options pricing shifts daily.

• 📉 IV crush post-event: Regardless of whether data is positive or negative, implied volatility will collapse after the catalyst resolves. This is why the butterfly (vs naked long calls) is the smarter structure - the short wings also experience IV crush, partially offsetting the decay on the long center strikes.

• 🏥 FDA approval timeline risk: Even strong positive data does not mean instant approval. An accelerated approval filing still takes 6-12 months. The stock may initially rally on data, then consolidate while the regulatory process plays out - leaving May 15 options with limited time to capture the full re-rating.

• 💊 Darovasertib approval doesn't save everything: Uveal melanoma (including metastatic) has an addressable patient population of only ~2,500-3,000 new cases per year in the US. Even with orphan drug pricing ($100K-$300K/year), peak revenue is capped. The long-duration thesis requires IDE849 in SCLC (much larger indication) to succeed.

• 🌍 Macro headwinds: The April 2026 risk-off environment driven by tariff uncertainty has hit the broader biotech sector. IDYA is trading well below analyst targets partly due to this indiscriminate selling. Macro tail risk (e.g., escalating trade war) could delay any recovery even if data is positive.

• 💸 Q1 2026 cash burn: Expected EPS of -$1.02 for the quarter ending March 2026. The company is burning roughly $80-85M per quarter to fund nine clinical programs. While the $1.05B cash position (runway to 2030) means there is no near-term financing risk, negative trial results could lead to pipeline deprioritization decisions and narrower burn guidance - which itself could weigh on sentiment.

• ⚔️ Competition in mUM: While there are no currently approved systemic therapies for mUM, other programs in development include tebentafusp (Immunocore), which has shown OS benefit in HLAA2-positive mUM. IDYA's OptimUM-02 targets specifically HLAA2-negative patients - a separate population - but any adverse regulatory or clinical development in the mUM space could create uncertainty.

• 📊 Vol/OI anomaly flags attention: With Vol/OI ratios of 75-86x on all legs and near-zero pre-existing OI, these trades are extraordinarily unusual and will attract regulatory attention. If the trade is linked to material non-public information about the trial results, there are compliance implications. This analysis assumes the trade is based on legitimate analysis of publicly available information and timing signals.

---

🎯 The Bottom Line

Here's the deal: In 52 seconds, someone built a $10.6M long call butterfly on IDEAYA Biosciences with maximum profit at $40 by May 15 - while IDYA's defining Phase 3 data readout is days away. The butterfly structure is the critical tell: this is not a reckless gamble. It is a precision instrument built to profit in a specific price zone ($35-$45) while minimizing downside on a binary event.

What this trade tells us:

• 🎯 The trader believes OptimUM-02 data is positive - a negative result makes the near-zero-cost butterfly construction pointless
• 💰 The $40 center strike (23% above spot) suggests the trader models a meaningful but not runaway rally - consistent with a first-look data positive with regulatory filing uncertainty ahead
• ⏰ The May 15 expiration brackets the data readout AND Q1 2026 earnings - two catalysts in one options window
• 📊 The MID fills across all four legs confirm institutional block execution - this is not retail volume
• 🧬 The OI destruction (all legs had <200 OI before today) means this is fresh conviction capital, not a roll or hedge

The OptimUM-02 data context: Prior Phase 1/2 data showed median PFS of ~7 months vs ~3 months historical control with an ORR of >30% vs ~10% in the randomized mUM population. If the Phase 2/3 trial confirms this signal with statistical significance across 435 patients, IDYA would have a filing-ready asset for the first approved therapy in metastatic uveal melanoma - a rare cancer with zero current approved options. Analyst consensus of ~$50 (vs today's $32.44) reflects exactly this scenario. With 14 analysts at Strong Buy and a high target of $65, the institutional conviction behind a positive readout is substantial.

If you are positioned for positive data:

• ✅ The butterfly structure is the sophisticated way to play it - consider mirroring it at smaller scale
• 📊 The $30 gamma support is your technical floor; a break below on negative data changes everything
• ⏰ Mark April 7-15 as the expected announcement window - be prepared for overnight moves
• 💡 Set limit orders rather than chasing at-the-open - biotech data moves are fast and violent in both directions

If you are watching from the sidelines:

• 🎯 A positive data release would likely gap the stock to $40+ immediately - entry after the fact at a lower risk/reward
• 📊 Consider waiting for post-data stabilization before entering; IV crush after the event means options become cheaper even if the stock moves in your favor
• 📈 The analyst consensus target of ~$50 with a high of $65 leaves substantial upside even for those entering post-catalyst
• ⏰ IDE849 SCLC data updates later in 2026 represent a completely separate, much larger addressable market catalyst

If you are cautious:

• ⚠️ Do not buy naked calls into the data readout without understanding you may lose 100% of premium if the trial fails
• 📉 Failed Phase 3 trials in rare disease oncology typically result in 40-60%+ single-day drawdowns - IDYA at $32 could trade to $15-$20 in a miss scenario
• 🛡️ The butterfly structure (near-zero net cost) is precisely the right risk management tool for this type of event; respect its elegance

Key dates to mark:

• 📅 April 7-15, 2026 (EST. WINDOW) - OptimUM-02 topline PFS data readout - THE moment of truth
• 📅 ~May 5, 2026 - Q1 2026 earnings (cash burn, pipeline updates, any early regulatory feedback)
• 📅 May 12, 2026 - Bank of America Healthcare Conference
• 📅 May 15, 2026 - THIS BUTTERFLY EXPIRES - 39 days from today
• 📅 May 19, 2026 - Stifel Targeted Oncology Virtual Forum
• 📅 H1 2026 - Three darovasertib Phase 3 programs expected to be running simultaneously
• 📅 End of 2026 - IDE849 Phase 1 data update + potential monotherapy registrational study in SCLC/NEC

Final verdict: IDEAYA is at an inflection point that comes once in a company's life - the first data readout of its lead asset in a pivotal registrational trial with no approved competition. The $10.6M butterfly is a sophisticated bet that the data delivers, the stock rallies into the $40 zone, and the position collects near its maximum value by May 15. The butterfly structure's near-zero cost on a negative outcome is the masterstroke: this trader bought optionality on a life-changing catalyst for essentially the cost of execution. That is a very smart trade.

The question is not whether the trade is smart. The question is whether darovasertib works. The data will tell us soon. 🧬

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and not financial advice. Clinical trial outcomes are inherently uncertain, and biotech options surrounding binary events can lose 100% of their value if the catalyst is negative. Butterfly spreads involve complex multi-leg execution with bid-ask spread costs on each leg. Always do your own research and consider consulting a licensed financial advisor before trading. Past options activity does not guarantee future stock performance.

---

About IDEAYA Biosciences: IDEAYA Biosciences is a precision medicine oncology company discovering and developing targeted therapeutics for patients with specific genetic profiles, with a focus on synthetic lethality biology. Lead asset darovasertib (IDE196) holds FDA Breakthrough Therapy and Fast Track designations and is being evaluated in three Phase 3 registrational trials in uveal melanoma. The company holds $1.05B in cash with runway to 2030 and a market cap of approximately $2.5B. NASDAQ: IDYA.